Form 4: Vertex Pharmaceuticals CEO Reshma Kewalramani Reports Stock Disposal
SEC Form 4 Filing
Reshma Kewalramani, CEO and President of Vertex Pharmaceuticals, reported disposing of 8,300 shares of common stock on February 10, 2025.
Summary
- On February 10, 2025, Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals, disposed of 8,300 shares of common stock.
- The transaction was executed at a price of $467.98 per share.
- Following the transaction, Kewalramani directly owns 116,918 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of a stock transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the actions of key executives.
Stakeholder Impact
- The disposal of shares by the CEO could be perceived neutrally or slightly negatively by shareholders, depending on the context and reasons behind the sale.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of the stock disposal transaction |
| 02/12/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.